Sold as Boniva. Every FDA application for this active ingredient: 2 branded and 18 generic.
As of Nov 16, 2026, FDA lists 20 applications for Ibandronate Sodium (sold as Boniva), first approved May 16, 2003, with 2 new uses approved and 0 published complete response letters.
| Ibandronate Sodium | Part D | $27.2M | +7% | 280,914 |
| Boniva | Part B | $75K | -38% | 443 |
| The Comparison of Ibandronate and Zoledronic Acid After Denosumab DiscontinuationPostmenopausal Osteoporosis, Postmenopausal Osteopenia · National Taiwan University Hospital | Phase 4 | Recruiting | Feb 12, 2026 |
| Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone MetastasesClear Cell Renal Cell Cancer (ccRCC), Clear Cell Renal Carcinoma · Kelly Fitzgerald, MD | Phase 2 | Recruiting | Jun 29, 2025 |
| May 16, 2003 | BonivaNDA 21455 · New molecular entity | Hoffmann La Roche | 15 | Discontinued |
| Jan 6, 2006 | BonivaNDA 21858 · New dosage form | Roche | 17 | Discontinued |
| Mar 19, 2012 | Ibandronate SodiumANDA 78948 | Apotex Inc | 6 | Marketed |
| Mar 19, 2012 | Ibandronate SodiumANDA 78995 | Pharmobedient | 3 | Discontinued |
| Mar 19, 2012 | Ibandronate SodiumANDA 78998 | Orbion Pharms | 4 | Marketed |
| Mar 20, 2012 | Ibandronate SodiumANDA 79003 | Watson Labs Teva | 3 | Discontinued |
| Apr 30, 2012 | Ibandronate SodiumANDA 78997 | Dr Reddys Labs Ltd | 7 | Marketed |
| Aug 15, 2012 | Ibandronate SodiumANDA 78996 | Sun Pharm Industries | 4 | Discontinued |
| Feb 14, 2014 | Ibandronate SodiumANDA 90853 | Sun Pharm | 3 | Discontinued |
| Sep 2, 2014 | Ibandronate SodiumANDA 202235 | Chemi Spa | 3 | Discontinued |
| Sep 2, 2014 | Ibandronate SodiumANDA 202671 | Pharmobedient | 5 | Discontinued |
| Sep 2, 2014 | Ibandronate SodiumANDA 203987 | Avet Lifesciences | 4 | Discontinued |
| Aug 19, 2015 | Ibandronate SodiumANDA 205332 | Eugia Pharma | 2 | Marketed |
| Oct 16, 2015 | Ibandronate SodiumANDA 204222 | Apotex | 4 | Marketed |
| Feb 5, 2016 | Ibandronate SodiumANDA 206058 | Accord Hlthcare | 3 | Marketed |
| Mar 11, 2016 | Ibandronate SodiumANDA 204502 | Aurobindo Pharma | 2 | Marketed |
| Oct 31, 2017 | Ibandronate SodiumANDA 206887 | Macleods Pharms | 3 | Marketed |
| Jun 16, 2021 | Ibandronate SodiumANDA 204329 | Nang Kuang Pharm Co | 1 | Discontinued |
| — | Ibandronate SodiumANDA 79002 | Cobalt Labs Inc | 0 | Discontinued |
| — | Ibandronate SodiumANDA 79194 | Teva Parenteral | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA